Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genzyme beats Street EPS

GENZ reported second quarter EPS of $0.34, which beat by $0.02 the consensus estimate and was up from $0.25

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE